On March 7th, Classys, a global leader in medical aesthetics under the leadership of CEO Seung-Han Baek, officially announced the initiation of sales for 'Ultraformer MPT,' marking the commencement of its comprehensive expansion into the European market.

The Shurink Universe stands as Classys' flagship product, boasting a worldwide cumulative sales figure surpassing 15,000 units. Distinguished by enhanced choices, increased speed, and a booster cartridge compared to its predecessor, the Shurink Universe has solidified its position as the premier high-intensity focused ultrasound (HIFU) brand in the South Korean market. Globally, it spearheads the beauty and medical device industry by driving the 'K-Beauty' trend.

Having introduced high-intensity focused ultrasound (HIFU) products in Europe since 2016 through the Ultraformer III (known as Shurink in South Korea), Classys has garnered high expectations among local potential customers for the innovative Ultraformer MPT. In Brazil, a key market for Classys, Ultraformer MPT received initial approval in 2022, achieving impressive sales of 250 units within approximately four months. Subsequently, in 2023, sales volume skyrocketed by 2.5 times, reaching 650 units, signaling a rapid expansion of the market.

A representative from Classys expressed, "The European region is an enticing market with significant potential, given the high number of consumers interested in skincare and beauty. We anticipate promising results in Europe, with a particular focus on Spain and Turkey."

Over the past five years, Classys has consistently maintained a robust annual growth rate, boasting a 31% average annual growth rate in revenue and a 39% average annual growth rate in earnings before interest, taxes, depreciation, and amortization (EBITDA). A company representative stated, "With increasing regulatory approvals for our key products in various countries each year, sustained growth is achievable through entering new markets and setting trends. Just last month, we obtained regulatory approval for Ultraformer MPT in Saudi Arabia, and we anticipate active sales performance in the Middle East market in the future. Additionally, we eagerly await approval for 'Volbella' in Brazil in April."